Home » Stocks » Solid Biosciences

Solid Biosciences Inc. (SLDB)

Stock Price: $3.72 USD -0.06 (-1.59%)
Updated Oct 19, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 171.50M
Revenue (ttm) n/a
Net Income (ttm) -106.80M
Shares Out 46.10M
EPS (ttm) -2.28
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 19, 2020
Last Price $3.72
Previous Close $3.78
Change ($) -0.06
Change (%) -1.59%
Day's Open 3.77
Day's Range 3.70 - 3.96
Day's Volume 513,882
52-Week Range 1.93 - 13.58

More Stats

Market Cap 171.50M
Enterprise Value 136.87M
Earnings Date (est) Mar 18, 2021
Ex-Dividend Date n/a
Shares Outstanding 46.10M
Float 30.61M
EPS (basic) -2.27
EPS (diluted) -2.28
FCF / Share -1.76
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 1.39M
Short Ratio 9.11
Short % of Float 4.54%
Beta 1.10
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 4.40
Revenue n/a
Operating Income -107.88M
Net Income -106.80M
Free Cash Flow -84.88M
Net Cash 34.63M
Net Cash / Share 0.75
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -85.84%
ROE -182.24%
ROIC -638.90%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (6)

Buy 1
Overweight 0
Hold 2
Underweight 0
Sell 3

Analyst Consensus: Hold

Price Target

(26.34% upside)
Current: $3.72
Target: 4.70
*Average 12-month price target from 5 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Operating Income-119-75.69-54.86-25.58-6.56
Net Income-117-74.80-52.12-21.54-6.38
Shares Outstanding40.2933.2613.651.700.85
Earnings Per Share-2.91-2.25-2.88-10.14-7.61
Operating Cash Flow-92.71-70.20-43.22-20.12-4.20
Capital Expenditures-4.39-7.78-2.28-0.39-
Free Cash Flow-97.10-77.97-45.50-20.51-4.20
Cash & Equivalents83.8512369.1637.8255.39
Total Debt7.071.03---
Net Cash / Debt76.7812269.1637.8255.39
Book Value80.05125-59.26-84.36-67.51
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Solid Biosciences Inc.
Country United States
Employees 121
CEO Ilan Ganot

Stock Information

Ticker Symbol SLDB
Stock Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Unique Identifier NASDAQ: SLDB
IPO Date January 26, 2018


Solid Biosciences, a life science company, engages in identifying and developing therapies for duchenne muscular dystrophy (DMD) in the United States. The company's lead product candidate is SGT-001, an adeno-associated viral vector-mediated gene transfer, which is in a Phase I/II clinical trial to restore functional dystrophin protein expression in patients' muscles. Its portfolio also comprises Anti-LTBP4, a monoclonal antibody that is in preclinical trials to reduce fibrosis and inflammation. In addition, the company engages in developing biomarkers and sensors; and Solid Suit program that includes the development of wearable assistive devices that focus on providing functional and therapeutic benefits to DMD patients. Solid Biosciences Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.